Risk Of Developing Liver Cancer After HCV Treatment

Wednesday, October 11, 2017

Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit

In Case You Missed It

Today over at Infectious Disease Advisor, media coverage on the study; Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus–Infected Persons: Results From ERCHIVES, is highlighted, the full-text article shared by @HenryEChang via Twitter, can be reviewed here.

Links
Hepatitis C Treatment With Direct-Acting Antivirals Confers Survival Benefit
October 11, 2017
Among patients with hepatitis C, direct-acting antiviral regimens paritaprevir/ritonavir, ombitasvir, and dasabuvir (PrOD) and ledipasvir/sofosbuvir (LDV/SOF) were shown to be associated with a significant improvement in survival, according to the results of a study published in Clinical Infectious Diseases ...

Full-Text Article

Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus–Infected Persons: Results From ERCHIVES

No comments:

Post a Comment